• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

    2/13/24 4:30:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email
    SC 13G/A 1 d778503dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Atea Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    04683R106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     


    CUSIP No. 04683R106    Schedule 13G    Page 1 of 7

     

     1   

     Names of Reporting Persons

     

     JPM Partners LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

     Sole Voting Power

     

     0

       6   

     Shared Voting Power

     

     5,925,000

       7   

     Sole Dispositive Power

     

     0

       8   

     Shared Dispositive Power

     

     5,925,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,925,000

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     7.1%

    12  

     Type of Reporting Person

     

     OO (Limited Liability Company)


    CUSIP No. 04683R106    Schedule 13G    Page 2 of 7

     

     1   

     Names of Reporting Persons

     

     Jean-Pierre Sommadossi

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5    

     Sole Voting Power

     

     2,237,914

       6   

     Shared Voting Power

     

     5,925,000

       7   

     Sole Dispositive Power

     

     2,237,914

       8   

     Shared Dispositive Power

     

     5,925,000

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     8,162,914

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     9.6%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 04683R106    Schedule 13G    Page 3 of 7

     

    ITEM 1. (a)

    Name of Issuer:

    Atea Pharmaceuticals, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    225 Franklin Street, Suite 2100, Boston, MA 02110.

     

    ITEM 2. (a)

    Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    JPM Partners LLC; and

    Jean-Pierre Sommadossi

     

      (b)

    Address or Principal Business Office:

    The business address of JPM Partners LLC is 2 Avery Street #21E, Boston, MA 02111. The business address of Dr. Sommadossi is c/o Atea Pharmaceuticals, Inc., 225 Franklin Street, Suite 2100, Boston, MA 02110.

     

      (c)

    Citizenship:

    JPM Partners LLC is a Delaware limited liability company. Dr. Sommadossi is a citizen of the United States.

     

      (d)

    Title of Class of Securities:

    Common stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    04683R106

     

    ITEM 3.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 4 of 7

     

    ITEM 4.

    Ownership.

    The ownership information below represents beneficial ownership of shares of Common Stock as of the date hereof, based upon 83,435,513 shares of Common Stock outstanding as of November 7, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

    (a-c)

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

       

    Sole

    power
    to vote

    or to

    direct

    the vote:

         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole

    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    JPM Partners LLC

         5,925,000        7.1 %      0        5,925,000        0        5,925,000  

    Jean-Pierre Sommadossi

         8,162,914        9.6 %      2,237,914        5,925,000        2,237,914        5,925,000  

    JPM Partners LLC is the record holder of 5,925,000 shares of Common Stock. Dr. Sommadossi is the manager of JPM Partners LLC and may be deemed to share beneficial ownership of the securities held by JPM Partner LLC. In addition, Dr. Sommadossi beneficially owns 2,237,914 shares of Common Stock, which includes 2,121,357 shares of Common Stock subject to stock options that are currently exercisable or will become exercisable within 60 days of the date hereof.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 5 of 7

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 04683R106    Schedule 13G    Page 6 of 7

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2024

     

    JPM Partners LLC
    By:  

    /s/ Jean-Pierre Sommadossi

    Name: Jean-Pierre Sommadossi
    Title: Manager
    Jean-Pierre Sommadossi

    /s/ Jean-Pierre Sommadossi


    CUSIP No. 04683R106    Schedule 13G    Page 7 of 7

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $AVIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings

    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

      4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 2:30:36 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      1/17/25 8:03:19 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Financials

    Live finance-specific insights

    See more
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. "I am pleased to share that we recently had a successful End-of-Phase 2 meeting with

      3/6/25 4:05:00 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/15/24 10:34:54 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      11/12/24 9:50:14 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      2/15/24 11:35:08 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results fo

      5/12/25 4:11:14 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

              Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 BOSTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the d

      5/7/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

      Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced it will virtually host a hepatitis C virus (HCV) key opi

      5/1/25 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

      SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

      5/14/25 6:21:56 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

      10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      5/12/25 4:45:23 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

      5/12/25 4:23:15 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

      8/13/24 7:25:26 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

      8/10/23 6:17:18 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

      JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

      3/2/22 10:09:39 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

      BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c

      2/10/22 7:00:00 AM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirsch Arthur S

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/24/25 6:52:21 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Kirsch Arthur S claimed ownership of 45,710 shares (SEC Form 3)

      3 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/24/25 6:47:18 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Hammond Janet Mj was granted 11,250 shares, covered exercise/tax liability with 14,134 shares and converted options into 46,800 shares, increasing direct ownership by 117% to 81,388 units (SEC Form 4)

      4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

      2/4/25 6:00:21 PM ET
      $AVIR
      Biotechnology: Pharmaceutical Preparations
      Health Care